PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
30867382-1	2019	Elobixibat is a novel small-molecule that acts as an inhibitor of the ileal bile acid transporter (IBAT), and used for chronic constipation in Japan.	elobixibat	0-10	solute carrier family 10 member 2	Homo sapiens	99-103
26197999-8	2015	Another study, in 36 patients with CC treated with high dose elobixibat; 15 mg or 20 mg/day or placebo for 14 days, was evaluated for changes in GLP-1.	elobixibat	61-71	glucagon	Homo sapiens	145-150
30129377-0	2018	Elobixibat, the first-in-class Ileal Bile Acid Transporter inhibitor, for the treatment of Chronic Idiopathic Constipation.	elobixibat	0-10	solute carrier family 10 member 2	Homo sapiens	31-58
30204504-6	2018	Areas covered: Rationale for IBAT inhibitor in therapeutics, and preclinical and clinical pharmacology of elobixibat: In vitro, elobixibat is a highly potent, selective IBAT inhibitor.	elobixibat	128-138	solute carrier family 10 member 2	Homo sapiens	29-33
30204504-6	2018	Areas covered: Rationale for IBAT inhibitor in therapeutics, and preclinical and clinical pharmacology of elobixibat: In vitro, elobixibat is a highly potent, selective IBAT inhibitor.	elobixibat	128-138	solute carrier family 10 member 2	Homo sapiens	169-173
21545606-0	2011	Randomised clinical trial: The ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation--a double-blind study.	elobixibat	69-74	solute carrier family 10 member 2	Homo sapiens	31-58
33278408-8	2021	Additionally, these uptakes were decreased by elobixibat, a selective ASBT inhibitor.	elobixibat	46-56	solute carrier family 10 member 2	Homo sapiens	70-74
35626847-6	2022	Attempting to reduce the total bile acids, we initiated off-label use of the ileal bile acid transporter (IBAT) inhibitor Elobixibat (Goofice ), later converted to Odevixibat (Bylvay ).	elobixibat	122-132	solute carrier family 10 member 2	Homo sapiens	77-104